Goserelin - AstraZeneca
Alternative Names: Goserelin acetate - AstraZeneca; Goserelin acetate implant - AstraZeneca; ZD-9393; ZoladexLatest Information Update: 14 May 2024
At a glance
- Originator AstraZeneca
- Class Antineoplastics; Infertility therapies; Oligopeptides; Pituitary hormone releasing hormones
- Mechanism of Action LHRH receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Breast cancer; Endometriosis; Female infertility; Prostate cancer; Uterine leiomyoma
Most Recent Events
- 07 May 2024 Health Canada approves sNDA for Goserelin 10.8mg every 12 weeks for the treatment of Breast cancer (Late-stage disease)
- 05 Feb 2024 The National Comprehensive Cancer Network® Breast Cancer Panel includes a category 2A recommendation for goserelin for hormone receptor positive (HR+) Breast cancer and Ovarian cancer
- 24 Oct 2023 The National Comprehensive Cancer Network® Head and Neck Cancers panel includes a category 2B recommendation for goserelin for salivary gland cancer